Pbgm01
GM1 Gangliosidosis
Gemma BiotherapeuticsPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the GM1 Gangliosidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2/3 | BB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
az-3102 Azafaros B.V. | Phase 3 | B |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Clofarabine Masonic Cancer Center, University of Minnesota | Phase 2 | B |
View all 9 →
Same molecule, other indications
Pbgm01 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →